Impact of capitation on free-standing dialysis facilities: Can you survive?

被引:20
作者
McMurray, SD [1 ]
Miller, J [1 ]
机构
[1] RENAL CARE GRP,NE INDIANA KIDNEY CTR,FT WAYNE,IN
关键词
capitation; ESRD cost; disease management; vascular access; hospital cost; ESRD;
D O I
10.1016/S0272-6386(97)90314-0
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Proposed changes in the Medicare reimbursement method for end-stage renal disease (ESRD) patients prompted us to study the total cost of caring for the ESRD patients in northeast Indiana over a 1-year period, We hoped to ascertain the actual cost of caring for patients treated with different modalities, determine if we could compete in a capitated environment, and identify areas in which we might reduce these expenses. Six patients new to dialysis and 29 patients already receiving treatment underwent follow-up evaluation for 1 year. We tracked their cost of care for 1 year in the outpatient setting as well as in the hospital, We found the cost of caring for all patients was $43,044 per year, Patients new to dialysis cost $3,164 more to care for than patients already receiving dialysis treatment, Hospitalization expense was the primary component of that difference, Continuous ambulatory peritoneal dialysis (CAPD) patients were $14,570 less costly per year to care for than hemodialysis patients, This differential primarily related to decreased hospitalization. Vascular access expenses were a major component of both the outpatient and inpatient cost for hemodialysis patients, Our yearly expenditures for all patients compared with suggested capitated Medicare reimbursement rates suggested that our program could be successful in a new reimbursement model, Several areas of possible cost reduction were identified, (C) 1997 by the National Kidney Foundation, Inc.
引用
收藏
页码:542 / 548
页数:7
相关论文
共 13 条
[1]  
BESARAB A, 1993, AM J KIDNEY DIS S1, V22, P3
[2]  
FARLEY DO, DESIGNING CAPITATION
[3]   REDUCTION IN RECOMBINANT-HUMAN-ERYTHROPOIETIN DOSES BY THE USE OF CHRONIC INTRAVENOUS IRON SUPPLEMENTATION [J].
FISHBANE, S ;
FREI, GL ;
MAESAKA, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 26 (01) :41-46
[4]  
HAKIM RM, 1995, J AM SOC NEPHROL, V6, P1319
[5]  
KALLICH JD, VASCULAR ACCESS PROC
[6]   EVIDENCE-BASED RECOMMENDATIONS FOR THE CLINICAL USE OF RECOMBINANT-HUMAN-ERYTHROPOIETIN [J].
MUIRHEAD, N ;
BARGMAN, J ;
BURGESS, E ;
JINDAL, KK ;
LEVIN, A ;
NOLIN, L ;
PARFREY, P .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 26 (02) :S1-S24
[7]  
*NIH, 1995, US REN DAT SYST 1995, P139
[8]   A COMPARISON OF INPATIENT AND OUTPATIENT MEDICARE ALLOWABLE CHARGES FOR CONTINUOUS AMBULATORY PERITONEAL AND CENTER HEMODIALYSIS-PATIENTS - A SINGLE-CENTER STUDY [J].
PROWANT, BF ;
KAPPEL, DF ;
CAMPBELL, A .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1986, 8 (04) :248-252
[9]  
RUBIN R, 1996, NEPHROL NEWS ISSUES, V29, P38
[10]  
TEEHAN BP, 1995, J AM SOC NEPHROL, V6, P139